ADIPOQ and Insulin resistance: Integrating biomarkers—such as high-sensitivity C-reactive protein (hs-CRP), adiponectin, leptin, and insulin resistance markers—could help elucidate the biological pathways linking BRI to mortality and potentially identify novel therapeutic targets.